Keros Therapeutics (KROS) Capital Expenditures (2019 - 2025)
Keros Therapeutics (KROS) posted Capital Expenditures of $1.5 million for Q4 2025, up 220.78% on a QoQ basis from -$1.3 million in Q3 2025, and up 434.95% year-over-year from $289000.0 in Q4 2024.
Keros Therapeutics (KROS) Capital Expenditures (2019 - 2025) Analysis & Trends
Keros Therapeutics' Capital Expenditures history runs 7 years deep, the most recent figure standing at $1.5 million for Q4 2025.
- Quarterly Capital Expenditures rose 434.95% year-over-year to $1.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.6 million (down 19.68% YoY) and the FY2025 annual result came in at $1.6 million, down 19.68% from the prior year.
- Capital Expenditures was $1.5 million for Q4 2025 at Keros Therapeutics, up from -$1.3 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $1.5 million in Q4 2025 and bottomed at -$1.3 million in Q3 2025.
- A 5-year average of $352250.0 and a median of $337500.0 in 2024 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2021 — Capital Expenditures slumped 850.0% — and 2024, when it surged 995.24%.
- Keros Therapeutics' Capital Expenditures stood at $159000.0 in 2021, then slumped by 61.01% to $62000.0 in 2022, then surged by 772.58% to $541000.0 in 2023, then sank by 46.58% to $289000.0 in 2024, then jumped by 434.95% to $1.5 million in 2025.
- Business Quant data shows KROS's Capital Expenditures at $1.5 million in Q4 2025, -$1.3 million in Q3 2025, and $720000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Keros Therapeutics | 377.42 Mn | 90.02 Mn | - | 1.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.55 Mn |
| Dec 31, 2025 | 1.55 Mn |
| Sep 30, 2025 | -1.28 Mn |
| Sep 30, 2025 | -1.28 Mn |
| Jun 30, 2025 | 720,000.00 |
| Jun 30, 2025 | 720,000.00 |
| Mar 31, 2025 | 565,000.00 |
| Mar 31, 2025 | 565,000.00 |
| Dec 31, 2024 | 289,000.00 |
| Dec 31, 2024 | 289,000.00 |
| Sep 30, 2024 | 386,000.00 |
| Sep 30, 2024 | 386,000.00 |
| Jun 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | 1.03 Mn |
| Mar 31, 2024 | 230,000.00 |
| Mar 31, 2024 | 230,000.00 |
| Dec 31, 2023 | 541,000.00 |
| Dec 31, 2023 | 541,000.00 |
| Sep 30, 2023 | 550,000.00 |
| Sep 30, 2023 | 550,000.00 |